Edition:
India

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

4.27USD
23 May 2019
Change (% chg)

-- (--)
Prev Close
$4.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
659,963
52-wk High
$19.59
52-wk Low
$2.64

Select another date:

Thu, Feb 28 2019

FDA flags concerns at Akorn's Amityville plant, shares slip

Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

UPDATE 2-FDA flags concerns at Akorn's Amityville plant, shares slip

Feb 28 Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

FDA flags sanitation concerns at Akorn's Amityville plant

Feb 28 Akorn Inc said on Thursday the U.S. Food and Drug Administration issued observations related to inspection of the company's manufacturing facility in Amityville, New York.

Akorn gets FDA warning letter for Illinois plant, shares drop

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

UPDATE 3-Akorn gets FDA warning letter for Illinois plant, shares drop

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

Akorn gets warning letter from the FDA

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority in April and May, 2018.

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE.

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

Select another date: